NCT04283474View on ClinicalTrials.gov

Phase 1 XG005-03 Topical Study

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

February 28, 2020

Primary Completion Date

January 28, 2021

Study Completion Date

January 28, 2021

Conditions
Pain
Interventions
DRUG

XG005-03

3 different concentrations (1%, 5%, 10%) of XG005-03 topical formulation

DRUG

Placebo

Placebo topical formulation

Trial Locations (1)

5000

CMAX Clinical Research Pty Ltd, Adelaide

All Listed Sponsors
lead

Xgene Pharmaceutical Group

INDUSTRY

NCT04283474 - Phase 1 XG005-03 Topical Study | Biotech Hunter | Biotech Hunter